ライフサイエンスコーパス: phorbol-12-myristate

1 on of receptor G-protein coupling induced by phorbol 12-myristate.

2 Here, we show that phorbol 12 myristate 13-acetate (PMA) inhibited Ca2+ inf

3 1 pre-monocyte macrophages (MDM) obtained by phorbol 12-myristate 13 acetate (PMA) treatment.

4 essin (100 and 500 pm) and the PKC activator phorbol 12-myristate 13-acetate (1 nm) each inhibited hu

5 ith (S730A)VACM-1/cul5 cDNA and treated with phorbol 12-myristate 13-acetate (10 and 100 nm) to induc

6 nteraction inhibitor, decreased 100 nm 4beta-phorbol 12-myristate 13-acetate (4beta-PMA)-induced co-i

7 Phorbol 12-myristate 13-acetate (a PKC activator) had si

8 dditive SERT inhibition by PD169316 and beta-phorbol 12-myristate 13-acetate (beta-PMA) indicated the

9 lowing UVB or 7,12-dimethylbenz(a)anthracene/phorbol 12-myristate 13-acetate (DMBA/PMA) treatment dev

10 protein kinase Cepsilon (PKCepsilon), while phorbol 12-myristate 13-acetate (PMA) activation of PKCe

11 In contrast, C1a avidly ligated phorbol 12-myristate 13-acetate (PMA) and anchored DKF-1

12 Here, we found that the PKC activators, phorbol 12-myristate 13-acetate (PMA) and bryostatin I,

13 mutant show enhanced ruffling in response to phorbol 12-myristate 13-acetate (PMA) and increased spee

14 nd produced IFN-gamma ex vivo in response to phorbol 12-myristate 13-acetate (PMA) and ionomycin stim

15 L-22 suppression, PP cells were treated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, whi

16 fect of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) and PKC inhibitors

17 bol-13-acetate-type tumor promoters, such as phorbol 12-myristate 13-acetate (PMA) and teleocidin, in

18 Using phorbol 12-myristate 13-acetate (PMA) as a tool to disse

19 nous NCX1 current (I(NaCa)) was increased by phorbol 12-myristate 13-acetate (PMA) but not by forskol

20 Activation of PKCs by phorbol 12-myristate 13-acetate (PMA) caused a redistrib

21 Although phorbol 12-myristate 13-acetate (PMA) caused limited tra

22 reatment of LNCaP prostate cancer cells with phorbol 12-myristate 13-acetate (PMA) causes a strong an

23 on-small cell lung cancer (NSCLC) cells with phorbol 12-myristate 13-acetate (PMA) during G1 phase in

24 d prevents activated platelet supernatant or phorbol 12-myristate 13-acetate (PMA) from inducing NETo

25 In this model, we show that phorbol 12-myristate 13-acetate (PMA) immediately activa

26 showed enhanced translocation in response to phorbol 12-myristate 13-acetate (PMA) in cells.

27 Activation of PKC with phorbol 12-myristate 13-acetate (PMA) in early G1 phase

28 Cells were also treated with phorbol 12-myristate 13-acetate (PMA) in the presence of

29 d selectivity for down-regulation by I3A and phorbol 12-myristate 13-acetate (PMA) in WEHI-231, HOP-9

30 Treatment with the PKC activator phorbol 12-myristate 13-acetate (PMA) increased N-cadher

31 Phorbol 12-myristate 13-acetate (PMA) increased receptor

32 n the present study it was demonstrated that phorbol 12-myristate 13-acetate (PMA) induced PLD2 activ

33 On the other hand, phorbol 12-myristate 13-acetate (PMA) inhibits OAG-media

34 In this study, we show that phorbol 12-myristate 13-acetate (PMA) is a potent stimul

35 nt with the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) is known to protec

36 styryl dye imaging, we studied the effect of phorbol 12-myristate 13-acetate (PMA) on activity-depend

37 Potentiation of Ca(v) 2.3 currents by phorbol 12-myristate 13-acetate (PMA) or acetyl-beta-met

38 We show that treatment with a combination of phorbol 12-myristate 13-acetate (PMA) plus ionophore A23

39 lls, activation of protein kinase C by 4beta-phorbol 12-myristate 13-acetate (PMA) produced ceramide

40 Phorbol 12-myristate 13-acetate (PMA) promotes PKC delta

41 Treatment of astrocytes with phorbol 12-myristate 13-acetate (PMA) quickly and prefer

42 ith HIV (JLat cells) were more responsive to phorbol 12-myristate 13-acetate (PMA) reactivation in th

43 Exposure of cells expressing Nox5 to phorbol 12-myristate 13-acetate (PMA) resulted in a slow

44 The PKC activator phorbol 12-myristate 13-acetate (PMA) stimulated apoE se

45 Moreover, incubation of cells with phorbol 12-myristate 13-acetate (PMA) stimulated phospha

46 Interestingly, phorbol 12-myristate 13-acetate (PMA) stimulated phospho

47 CE), and this process is further enhanced by phorbol 12-myristate 13-acetate (PMA) stimulation.

48 Phorbol 12-myristate 13-acetate (PMA) switches on DKF-1

49 lastase (NE) release following activation by phorbol 12-myristate 13-acetate (PMA) than cells isolate

50 4 channels were inhibited by a PKC activator phorbol 12-myristate 13-acetate (PMA) through reduction

51 by collagenase digestion and incubated with phorbol 12-myristate 13-acetate (PMA) to activate PKC or

52 c/nPKC is either activated by short-term phorbol 12-myristate 13-acetate (PMA) treatment or down-

53 Phorbol 12-myristate 13-acetate (PMA) treatment resulted

54 l)maleim ide], or PKC depletion by prolonged phorbol 12-myristate 13-acetate (PMA) treatment, attenua

55 R) activity, in combination with IL-1beta or phorbol 12-myristate 13-acetate (PMA) treatment, results

56 In perforated-patch recordings, phorbol 12-myristate 13-acetate (PMA) up-regulated the c

57 studies with pharmacological agonists (e.g. phorbol 12-myristate 13-acetate (PMA)) indicate that pro

58 Indeed, phorbol 12-myristate 13-acetate (PMA), a direct activato

59 In the current work we used phorbol 12-myristate 13-acetate (PMA), a well recognized

60 cells were stimulated with thrombopoietin or phorbol 12-myristate 13-acetate (PMA), alphaIIbbeta3 bec

61 ion of the protein and by the phorbol ester, phorbol 12-myristate 13-acetate (PMA), an activator of p

62 In addition, phorbol 12-myristate 13-acetate (PMA), but not 4alpha-PM

63 nduced by stimulation with the phorbol ester phorbol 12-myristate 13-acetate (PMA), but not by ionomy

64 ure to the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), enhanced TaALMT1-

65 nts or the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), in primary HUVECs

66 h the potent protein kinase C (PKC) agonist, phorbol 12-myristate 13-acetate (PMA), induces a transie

67 n kinase C activator, topical Ing3A, but not phorbol 12-myristate 13-acetate (PMA), inhibited the gro

68 Although bryostatin 1, like phorbol 12-myristate 13-acetate (PMA), is a potent activ

69 factor (TNF), interleukin-1beta (IL-1beta), phorbol 12-myristate 13-acetate (PMA), lipopolysaccharid

70 demonstrated that activation of PKCalpha by phorbol 12-myristate 13-acetate (PMA), or ectopic expres

71 ion with adenosine-5'-triphosphate (ATP) and phorbol 12-myristate 13-acetate (PMA), results in a cati

72 ith p38 kinase inducer, hydrogen peroxide or phorbol 12-myristate 13-acetate (PMA), U6 promoter activ

73 rogenase (LDH) isoforms after treatment with phorbol 12-myristate 13-acetate (PMA), which activates M

74 tubes were treated with the PKC/D1 activator phorbol 12-myristate 13-acetate (PMA), which acts as a D

75 factor CalDAG-GEFI inhibited SDF-1alpha- and phorbol 12-myristate 13-acetate (PMA)-induced adhesion t

76 ion of wild-type PKD3 in LNCaP cells blocked phorbol 12-myristate 13-acetate (PMA)-induced apoptosis

77 s revealed that, notably, androgens modulate phorbol 12-myristate 13-acetate (PMA)-induced apoptosis

78 ibition of NF-kappaB reversed both H2O2- and phorbol 12-myristate 13-acetate (PMA)-induced decrease i

79 in human myeloid HL-60 cells following their phorbol 12-myristate 13-acetate (PMA)-induced differenti

80 Here we studied the role of PK in phorbol 12-myristate 13-acetate (PMA)-induced megakaryoc

81 Ankrd1 deletion enhanced both basal and phorbol 12-myristate 13-acetate (PMA)-induced MMP13 prom

82 WASP expression blocked HCMV-induced but not phorbol 12-myristate 13-acetate (PMA)-induced monocyte m

83 vestigated the signalling pathway regulating phorbol 12-myristate 13-acetate (PMA)-induced MUC5AC gen

84 Both basal and phorbol 12-myristate 13-acetate (PMA)-induced NADPH oxid

85 Bryostatin 1 impairs phorbol 12-myristate 13-acetate (PMA)-induced tumor prom

86 nsfer (BRET), we detected a constitutive and phorbol 12-myristate 13-acetate (PMA)-induced ubiquitina

87 In addition, Dexras1 significantly reduced phorbol 12-myristate 13-acetate (PMA)-stimulated AC2 act

88 Phorbol 12-myristate 13-acetate (PMA)-stimulated but not

89 leukocyte protease profiles under naive and phorbol 12-myristate 13-acetate (PMA)-stimulated conditi

90 Phorbol 12-myristate 13-acetate (PMA)-stimulated PMNs ad

91 gh tyrosine phosphorylation in H(2)O(2)- and phorbol 12-myristate 13-acetate (PMA)-treated cardiomyoc

92 ) was combined with human PMN induced with 4-phorbol 12-myristate 13-acetate (PMA).

93 7(phox) and activated Rac with activation by phorbol 12-myristate 13-acetate (PMA).

94 of MCF-7 cells with a potent PKC activator, phorbol 12-myristate 13-acetate (PMA).

95 We investigated cis elements regulated by phorbol 12-myristate 13-acetate (PMA).

96 isoforms by 24 h pretreatment of cells with phorbol 12-myristate 13-acetate (PMA).

97 inhibitor, TAPI-1, while it was promoted by phorbol 12-myristate 13-acetate (PMA).

98 sensitive or resistant to the tumor promoter phorbol 12-myristate 13-acetate (PMA).

99 was directly activated by the phorbol ester phorbol 12-myristate 13-acetate (PMA).

100 n the presence of inflammatory mediators and phorbol 12-myristate 13-acetate (PMA).

101 m untreated HeLa cells or cells treated with phorbol 12-myristate 13-acetate (PMA).

102 ld be achieved in mitotic cells treated with phorbol 12-myristate 13-acetate (PMA).

103 ty of RSK2 purified from cells stimulated by phorbol 12-myristate 13-acetate (PMA).

104 n PC1(lo) cells when stimulated with LPS and phorbol 12-myristate 13-acetate (PMA).

105 ator of conventional and novel PKC isoforms, phorbol 12-myristate 13-acetate (PMA).

106 ct on proinflammatory cytokine production of phorbol 12-myristate 13-acetate (PMA)/ionomycin-stimulat

107 Phorbol ester [phorbol 12-myristate 13-acetate (PMA)] treatment of huma

108 The PKC activator, phorbol 12-myristate 13-acetate (PMA, 0.5 microm) had no

109 e concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent

110 be modulated by treatment with anisomycin or phorbol 12-myristate 13-acetate (PMA/12-O-tetradecanoylp

111 PKC activation by phorbol 12-myristate 13-acetate (PMA; 100 nM; 30 minutes

112 the expression of K-Rta or by treatment with phorbol 12-myristate 13-acetate (TPA) and/or n-butyrate.

113 Differentiation of HL-60 cells with phorbol 12-myristate 13-acetate (TPA) rendered the cell

114 The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), indu

115 ecrosis factor alpha, lipopolysaccharide, or phorbol 12-myristate 13-acetate + CI.

116 ) markedly enhanced superoxide production in phorbol 12-myristate 13-acetate - and fMet-Leu-Phe-stimu

117 a by TCR-independent polyclonal stimulation (phorbol 12-myristate 13-acetate [PMA] plus ionomycin).

118 Phorbol 12-myristate 13-acetate also potentiated cyclic

119 as more prominent when NFAT was activated by phorbol 12-myristate 13-acetate and calcium ionophore io

120 ription complex in the induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines.

121 nt for the synergistic induction of MnSOD by phorbol 12-myristate 13-acetate and cytokines.

122 Other ERK activators, phorbol 12-myristate 13-acetate and epidermal growth fac

123 CRF was observed than that mediated by 4beta-phorbol 12-myristate 13-acetate and forskolin alone, bei

124 compatible with the concomitant treatment by phorbol 12-myristate 13-acetate and forskolin.

125 r rottlerin prevented the effects induced by phorbol 12-myristate 13-acetate and human neutrophil ela

126 Phorbol 12-myristate 13-acetate and ionomycin stimulated

127 this effect is only detected following cell phorbol 12-myristate 13-acetate and ionomycin stimulatio

128 d could be bypassed through stimulation with phorbol 12-myristate 13-acetate and ionomycin.

129 x expression or in Jurkat cells treated with phorbol 12-myristate 13-acetate and ionomycin.

130 ficantly reduced NK- and T-cell responses to phorbol 12-myristate 13-acetate and ionomycin.

131 on of MEK and ERK following stimulation with phorbol 12-myristate 13-acetate and ionomycin.

132 , T-plastin-negative PBLs were stimulated by phorbol 12-myristate 13-acetate and ionomycin.

133 fG to the iNOS promoter could be enhanced by phorbol 12-myristate 13-acetate and suppressed by the pr

134 Isoproterenol also blocked ERK downstream of phorbol 12-myristate 13-acetate and the P2X(7) and epide

135 amma expression in response to ionomycin and phorbol 12-myristate 13-acetate and weakly enhanced expr

136 ls and NCI-H292 airway epithelial cells with phorbol 12-myristate 13-acetate and with human neutrophi

137 Similar results were obtained with phorbol 12-myristate 13-acetate as well as activation of

138 y several microorganism membrane components, phorbol 12-myristate 13-acetate as well as by amyloid fi

139 The protein kinase C (PKC) activator phorbol 12-myristate 13-acetate blunted VR1 desensitizat

140 Epidermal growth factor or the phorbol ester phorbol 12-myristate 13-acetate caused rapid phosphoryla

141 tion of T cells with concanavalin A, but not phorbol 12-myristate 13-acetate combined with ionomycin,

142 hat treatment with the inflammatory stimulus phorbol 12-myristate 13-acetate downregulates meprin alp

143 found that treatment with both ionomycin and phorbol 12-myristate 13-acetate ensured efficient nuclea

144 Ionomycin and phorbol 12-myristate 13-acetate further increased the ac

145 n cleavage of Pref-1 is markedly enhanced by phorbol 12-myristate 13-acetate in a dose- and time-depe

146 The apoptotic effect of phorbol 12-myristate 13-acetate in LNCaP cells was impai

147 ro and membrane translocation in response to phorbol 12-myristate 13-acetate in LNCaP cells.

148 o, with only marginal remaining activity for phorbol 12-myristate 13-acetate in vivo.

149 Phorbol 12-myristate 13-acetate increased intracellular

150 or rottlerin treatment versus activation by phorbol 12-myristate 13-acetate indicated that 2B15 unde

151 In contrast, phorbol 12-myristate 13-acetate induced low amplitude ca

152 se mammary tumor virus promoter activity and phorbol 12-myristate 13-acetate induction of endogenous

153 Conversely, the PKC agonist phorbol 12-myristate 13-acetate mimicked the Ang II effe

154 ibitory effect of AngII or the PKC activator phorbol 12-myristate 13-acetate on ROMK channels.

155 Moreover, enhancement of Egr-1 protein with phorbol 12-myristate 13-acetate or an egr-1 expression v

156 leasing peptide receptor treated with either phorbol 12-myristate 13-acetate or bombesin, respectivel

157 d PKCdelta (wild-type PKCdelta stimulated by phorbol 12-myristate 13-acetate or constitutively active

158 the activity of ADAM17, activated by either phorbol 12-myristate 13-acetate or EGF.

159 Upon stimulation with phorbol 12-myristate 13-acetate or fMet-Leu-Phe, p40(pho

160 Activation of PKCepsilon by phorbol 12-myristate 13-acetate or H(2)O(2) resulted in

161 Treatment of BMT or HSCT neutrophils with phorbol 12-myristate 13-acetate or rapamycin resulted in

162 lly increases in cardiomyocytes treated with phorbol 12-myristate 13-acetate or the alpha(1)-adrenerg

163 uction of differentiation of thymocytes with phorbol 12-myristate 13-acetate plus ionomycin results i

164 ILC2s were then stimulated with phorbol 12-myristate 13-acetate plus ionomycin, IL-25 pl

165 reover, ILC2s expressed CD154 in response to phorbol 12-myristate 13-acetate plus ionomycin, IL-25/IL

166 ied a subset of CD8(+) T cells refractory to phorbol 12-myristate 13-acetate plus ionomycin-induced E

167 MB-231 and MDA-MB-435, upon stimulation with phorbol 12-myristate 13-acetate plus ionomycin.

168 in and pertussis toxin but were abolished by phorbol 12-myristate 13-acetate pretreatment, suggesting

169 ressing PKCdelta followed by incubation with phorbol 12-myristate 13-acetate resulted in an increase

170 tive PKD or PKD activation by treatment with phorbol 12-myristate 13-acetate results in phosphorylati

171 We found that acute activation of PKC with phorbol 12-myristate 13-acetate shortened carbachol-evok

172 ound that activation of the PKC pathway with phorbol 12-myristate 13-acetate significantly increased

173 Phorbol 12-myristate 13-acetate stimulation of both cell

174 way in lymphocytes after antigen receptor or phorbol 12-myristate 13-acetate stimulation, whereas CD4

175 NA synthesis of CHRF cells in the absence of phorbol 12-myristate 13-acetate stimulation.

176 pidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation.

177 that addition of the NADPH oxidase activator phorbol 12-myristate 13-acetate to nitric oxide-producin

178 effect of conditioned medium collected after phorbol 12-myristate 13-acetate treatment could be inhib

179 esicle-like structures formed in response to phorbol 12-myristate 13-acetate treatment.

180 ele, and this differential is accentuated by phorbol 12-myristate 13-acetate treatment.

181 and insulinoma cells, either with or without phorbol 12-myristate 13-acetate treatment.

182 i-T cell receptor (TCR) antibody without the phorbol 12-myristate 13-acetate usually used previously.

183 cation of PKCdelta to the plasma membrane by phorbol 12-myristate 13-acetate was enhanced in p23-depl

184 S) in response to angiotensin II (Ang II) or phorbol 12-myristate 13-acetate was markedly reduced in

185 th platelet activating factor, ionomycin, or phorbol 12-myristate 13-acetate was significantly enhanc

186 The increases by strain, PGE2, Wnt-3a, and phorbol 12-myristate 13-acetate were attenuated by inhib

187 selectively prevents nPKCdelta depletion by phorbol 12-myristate 13-acetate when coapplied, coincide

188 protein kinase C (PKC) by the phorbol ester (phorbol 12-myristate 13-acetate) induces ceramide format

189 th the literature, at room temperature, PMA (phorbol 12-myristate 13-acetate) produced a large reprod

190 PKC, experiments with the PKC activator PMA (phorbol 12-myristate 13-acetate) were performed.

191 increased relative basal and phorbol ester (phorbol 12-myristate 13-acetate)-induced PKC activity bu

192 CREB activation depends on a phorbol ester (phorbol 12-myristate 13-acetate)-sensitive protein kinas

193 ment of exocytosis by the phorbol ester PMA (phorbol 12-myristate 13-acetate).

194 ERK1/2 are also activated in most cells by phorbol 12-myristate 13-acetate, a classical inhibitor o

195 phosphorylation at Ser(430) is stimulated by phorbol 12-myristate 13-acetate, an activator of classic

196 chemical activators of shedding (ionomycin, phorbol 12-myristate 13-acetate, and 4-aminophenylmercur

197 The pharmacologic inhibitors chlorpromazine, phorbol 12-myristate 13-acetate, and cytochalasin D caus

198 stimulatory effects of PGE(1), 8-bromo-cAMP, phorbol 12-myristate 13-acetate, and okadaic acid.

199 nteractions among carbachol, PKC inhibitors, phorbol 12-myristate 13-acetate, and thapsigargin to mod

200 phosphorylation, including the phorbol ester phorbol 12-myristate 13-acetate, anisomycin, calyculin A

201 lowed treatment of resident macrophages with phorbol 12-myristate 13-acetate, but treatment with lipo

202 tion induced by tumor necrosis factor (TNF), phorbol 12-myristate 13-acetate, cigarette smoke, okadai

203 polysaccharide, interleukin-1, okadaic acid, phorbol 12-myristate 13-acetate, H(2)O(2), and cigarette

204 r carcinogens and inflammatory stimuli (e.g. phorbol 12-myristate 13-acetate, H2O2, cigarette smoke c

205 on by serotonin showed a similar response to phorbol 12-myristate 13-acetate, implicating a potential

206 Exogenously added diacylglycerol or phorbol 12-myristate 13-acetate, known activators of PKC

207 hibited NF-kappaB activation induced by TNF, phorbol 12-myristate 13-acetate, lipopolysaccharide, and

208 agents, such as cigarette smoke condensate, phorbol 12-myristate 13-acetate, okadaic acid, hydrogen

209 by N-formyl-methionyl-leucyl-phenylalanine, phorbol 12-myristate 13-acetate, or grass pollen allerge

210 low-density lipoprotein, 7-ketocholesterol, phorbol 12-myristate 13-acetate, or macrophage colony-st

211 s are stimulated with lysophosphatidic acid, phorbol 12-myristate 13-acetate, or serum, but not in re

212 When cells were incubated with 200 nm phorbol 12-myristate 13-acetate, the appearance of the M

213 eceptor mimetic carbachol, the phorbol ester phorbol 12-myristate 13-acetate, the Ca(2+) ionophore io

214 ent of pancreatoids with (-)-Indolactam-V or phorbol 12-myristate 13-acetate, two protein kinase C ac

215 NFAT1 upon co-stimulation with ionomycin and phorbol 12-myristate 13-acetate, whereas anergic transcr

216 kinase C activation with the phorbol ester, phorbol 12-myristate 13-acetate, which has also been sho

217 s most effective in preventing constitutive, phorbol 12-myristate 13-acetate-, and ionomycin-stimulat

218 t of Vpr on monocyte-derived macrophages and phorbol 12-myristate 13-acetate-activated THP1 macrophag

219 All PKDs are regulated by DAG/phorbol 12-myristate 13-acetate-binding C1 domains and a

220 implicate PKD1-Ser744 phosphorylation in the phorbol 12-myristate 13-acetate-dependent mechanism that

221 )-induced PKC activity but were defective in phorbol 12-myristate 13-acetate-induced actin cytoskelet

222 ed proliferation, and provided resistance to phorbol 12-myristate 13-acetate-induced apoptosis in LNC

223 RNA (siRNA), and short hairpin RNA abrogated phorbol 12-myristate 13-acetate-induced down-regulation

224 ved GC synthesis protected skin from topical phorbol 12-myristate 13-acetate-induced inflammatory ass

225 s, and delayed apoptosis and cell death upon phorbol 12-myristate 13-acetate-induced Mk differentiati

226 lloproteinase-17 (ADAM17) is responsible for phorbol 12-myristate 13-acetate-induced release of TMEFF

227 The C1b domain mediates phorbol 12-myristate 13-acetate-induced translocation an

228 cked by PKC inhibitors, unlike carbachol- or phorbol 12-myristate 13-acetate-initiated phosphorylatio

229 I, Ro-32-0432, Go6983, and Rottlerin, by the phorbol 12-myristate 13-acetate-mediated and time-depend

230 Only SFHFKSGSL, in PKCdelta-transfected phorbol 12-myristate 13-acetate-stimulated cells, caused

231 ceptor-mediated IL-4 secretion but inhibited phorbol 12-myristate 13-acetate-stimulated IL-4 secretio

232 d reduced to alpha-ClFOH in both control and phorbol 12-myristate 13-acetate-stimulated neutrophils.

233 signal of O2[Symbol: see text] generated by phorbol 12-myristate 13-acetate-stimulated neutrophils.

234 the L-selectin tail with cell extracts from phorbol 12-myristate 13-acetate-stimulated Raw 264.7 mac

235 MMP-9 transcription was decreased in phorbol 12-myristate 13-acetate-stimulated THP-1 macroph

236 kines IL-1beta and TNF-alpha were reduced in phorbol 12-myristate 13-acetate-treated MCs developed fr

237 more, 7E4 abrogated LFA-1/ICAM-1 adhesion of phorbol 12-myristate 13-acetate-treated MOLT-4 cells.

238 twice weekly application of proinflammatory phorbol 12-myristate 13-acetate.

239 , but was indispensable for such activity by phorbol 12-myristate 13-acetate.

240 hyperproduction of IL-6 in response to 4beta phorbol 12-myristate 13-acetate.

241 n a model of toxic contact eczema induced by phorbol 12-myristate 13-acetate.

242 cluding lipopolysaccharide, doxorubicin, and phorbol 12-myristate 13-acetate.

243 tion by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate.

244 12-dimethylbenz[a]anthracene and promoted by phorbol 12-myristate 13-acetate.

245 zymosan and modestly reduced activity after phorbol 12-myristate 13-acetate.

246 ct the Shp2-independent Erk1/2 activation by phorbol 12-myristate 13-acetate.

247 xpressed high levels of CD28 when exposed to phorbol 12-myristate 13-acetate.

248 arget genes, c-fos and egr-1, in response to phorbol 12-myristate 13-acetate.

249 N-formyl-methionyl-leucyl-phenylalanine, or phorbol 12-myristate 13-acetate.

250 KCdelta downstream effectors ROCK and JNK by phorbol 12-myristate 13-acetate.

251 r cells were cultured unstimulated (U), with phorbol 12-myristate 13-acetate/ionomycin (PI) or lipopo

252 tokine production upon stimulation with both phorbol 12-myristate 13-acetate/ionomycin and CMV-peptid

253 ucers of p100 processing, but not by mitogen phorbol 12-myristate 13-acetate/ionomycin or cytokine tu

254 but also accelerated T cell activation under phorbol 12-myristate 13-acetate/ionomycin treatment cond

255 l activation through CD3/CD28 stimulation or phorbol 12-myristate 13-acetate/ionomycin treatment enha

256 of IFNG-luciferase constructs and found that phorbol 12-myristate 13-acetate/ionomycin-induced transc

257 ic knockdown of GIMAP6 led to enhancement of phorbol 12-myristate 13-acetate/ionomycin-mediated activ

258 CPIP1 by MG132 abrogated HIV-1 production in phorbol 12-myristate 13-acetate/ionomycin-stimulated hum

259 lls were cultured overnight with and without phorbol 12-myristate 13-acetate/ionomycin.

260 scriptional responses to the tumor promoter, phorbol-12-myristate 13-acetate (PMA), in cells with var

261 rt studies of HIF-1alpha induction following phorbol-12-myristate 13-acetate (PMA)-induced differenti

262 ecame phosphorylated at Ser27 in response to phorbol-12-myristate 13-acetate and this was prevented b

263 During phorbol-12-myristate 13-acetate-induced differentiation

264 nels (Ca(v)) 2.2 currents are potentiated by phorbol-12-myristate, 13-acetate (PMA), whereas Ca(v) 2.

265 e (MCh), a muscarinic M1 receptor agonist or phorbol-12-myristate, 13-acetate (PMA).

266 and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.

267 le of putrescine, spermidine and spermine in phorbol 12-myristate-13-acetate (PMA)-induced macrophage

268 In contrast, phorbol 12-myristate-13-acetate (TPA) -induced cleavage

269 Exposure of cells to 3 or 100 nM 4beta-phorbol 12-myristate-13-acetate induced co-immunoprecipi

270 ous inflammatory response that is induced by phorbol 12-myristate-13-acetate, a model of irritant con

271 lated cyclooxygenase-2 expression induced by phorbol 12-myristate-13-acetate.

272 In a transmembrane invasion assay, phorbol-12-myristate-13-acetate (100 nmol/L) increased t

273 Here, we show that 4beta-phorbol-12-myristate-13-acetate (4betaPMA), a stereosele

274 iR-21 are induced by common stimuli, such as phorbol-12-myristate-13-acetate (PMA) and androgens, but

275 cells, the action of the PKC activator 4beta-phorbol-12-myristate-13-acetate (PMA) evokes ceramide fo

276 K562 chronic myelogenous leukemia cells with phorbol-12-myristate-13-acetate (PMA) induces megakaryoc

277 Treatment of cells with the PKC activator phorbol-12-myristate-13-acetate (PMA) potently stimulate

278 directly on-chip and free radical release by phorbol-12-myristate-13-acetate (PMA) stimulation was de

279 isolated human monocytes pre-activated with phorbol-12-myristate-13-acetate (PMA) were added back in

280 bitor peptide and mimicked by application of phorbol-12-myristate-13-acetate (PMA), implicating a PKC

281 Phorbol-12-myristate-13-acetate (PMA)-induced mucin hype

282 -eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferat

283 skin upon treatment with the tumor promoter phorbol-12-myristate-13-acetate (PMA).

284 or without UDCA and further activated using phorbol-12-myristate-13-acetate (PMA).

285 Whole rat lenses were treated with phorbol-12-myristate-13-acetate (TPA) to activate PKCgam

286 rmoset lymphoblastoid cells by phorbol ester phorbol-12-myristate-13-acetate (TPA).

287 The stimulation of tissue with phorbol-12-myristate-13-acetate and ionomycin, recapitul

288 ulation by either anti-CD3 plus anti-CD28 or phorbol-12-myristate-13-acetate and ionomycin.

289 HL-60 cells treated with phorbol-12-myristate-13-acetate differentiate to a macro

290 In contrast, the phorbol ester PMA (phorbol-12-myristate-13-acetate, a pharmacological mimic

291 , or the PKCalpha-activator and TJ-disruptor phorbol-12-myristate-13-acetate, similarly reduced TJ in

292 1 is mobile on resting cells but immobile on phorbol-12-myristate-13-acetate-activated cells.

293 the role of cysteine string protein (csp) in phorbol-12-myristate-13-acetate-evoked cortical granule

294 -transformed B-cell lines partially restored phorbol-12-myristate-13-acetate-induced cell death.

295 subset of phenotypic changes that occur upon phorbol-12-myristate-13-acetate-induced differentiation

296 In addition, LeTx repressed phorbol-12-myristate-13-acetate-induced mouse mammary tu

297 ed after activation of protein kinase C with phorbol-12-myristate-13-acetate.

298 s oocytes by the protein kinase C activator, phorbol-12-myristate-13-acetate.

299 Phorbol-12-myristate-13-acetate/ionomycin-induced MAPK s

300 tuitary tumor-derived cell line treated with phorbol-12-myristate-13-acetate; these results were conf